Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 3

Interventions

Cisplatin 3199Cyclophosphamide 3193Carboplatin 2973Radiotherapy 2786Paclitaxel 2717Gemcitabine 2572pembrolizumab 2382Bevacizumab 2208Docetaxel 2199Fluorouracil 1851Capecitabine 1831Oxaliplatin 1742Dexamethasone 1604Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1385Etoposide 1345Irinotecan 1248Leucovorin 1225Drug Therapy 1204Cytarabine 1130Pemetrexed 1074fludarabine 1061Specimen Handling 1016Vincristine 964Cetuximab 945Trastuzumab 944Prednisone 941Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
HBM9161 × Clear all
NCT05332210 2026-04-28

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
111 enrolled

Myasthenia Gravis

NCT04346888 2023-03-08

A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 2 Completed
30 enrolled

Myasthenia Gravis

NCT05039190 2023-03-08

MG

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
132 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡